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Abstract 
Background: Glucagon‑like peptide 1 (GLP‑1) analogs protect a variety of cell types against oxidative damage and 
vascular and neuronal injury via binding to GLP‑1 receptors. This study aimed to investigate the effects of the GLP‑1 
analogs exendin‑4 and liraglutide on cerebral blood flow, reactive oxygen species production, expression of oxidative 
stress‑related proteins, cognition, and pelvic sympathetic nerve‑mediated bladder contraction after middle cerebral 
artery occlusion (MCAO) injury in the db/db mouse model of diabetes.
Results: Sixty minutes of MCAO increased blood and brain reactive oxygen species counts in male db/db mice, as 
revealed by dihydroethidium staining. MCAO also increased nuclear factor‑κB and intercellular adhesion molecule‑1 
expression and decreased cerebral microcirculation. These effects were attenuated by treatment with exendin‑4 
or liraglutide. MCAO did not affect basal levels of phosphorylated Akt (p‑Akt) or endothelial nitric oxide synthase 
(p‑eNOS); however, exendin‑4 and liraglutide treatments significantly enhanced p‑Akt and p‑eNOS levels, indicating 
activation of the p‑Akt/p‑eNOS signaling pathway. MCAO‑induced motor and cognitive deficits and micturition dys‑
function, indicated by reduced pelvic nerve‑mediated voiding contractions and increased nonvoiding contractions, 
were also partially attenuated by exendin‑4 treatment.
Conclusions: The above data indicate that treatment with GLP‑1 agonists exerts protective effects against oxidative, 
inflammatory, and apoptotic damage in brain areas that control parasympathetic/pelvic nerve‑mediated voiding 
contractions and cognitive and motor behaviors in a diabetic mouse model.
Keywords: Cerebral microcirculation, GLP‑1 agonist, Middle cerebral artery occlusion, Oxidative stress, Pelvic nerve, 
Voiding function
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Background
Diabetes mellitus is a major independent risk factor for 
stroke occurrence; patients with type 2 diabetes have 
twice the risk of stroke compared to the general popula-
tion [1] and are at markedly increased risk of death due 
to cerebrovascular disease [2, 3]. The precise mechanism 
for diabetes-induced cerebral and vascular damage may 
involve a causal relationship between hyperglycemia-
evoked oxidative stress and inflammation [4–7]. Type 
2 diabetes can cause oxidative stress, leading to vascu-
lar complications and stroke [8–11]. Acute hemispheric 
stroke may, in turn, result in urinary incontinence. Blad-
der dysfunction has been reported in patients suffering 
from stroke [12]. Additionally, rats subjected to middle 
cerebral artery occlusion (MCAO), which disrupts the 
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cholinergic pathway between the frontal cortex and the 
nucleus basalis [13], show increased voiding frequency, 
inefficient voiding [14], and decreased bladder capac-
ity [15]. Treating MCAO injury by intracerebrovascu-
lar administration of the acetylcholinesterase inhibitor 
donepezil increases bladder capacity [15].
Glucagon-like peptide-1 (GLP-1) is a gut hormone 
secreted by the small intestine that exerts a glucose-
dependent stimulatory effect on insulin release by bind-
ing to GLP-1 receptors (GLP-1Rs) on pancreatic β-cells 
[16, 17]. GLP-1 also stimulates β-cell proliferation [18] 
and enhances β-cell differentiation [19]. GLP-1 and its 
longer-acting analogs exendin-4 (Ex-4) and liraglutide 
(Lir) protect a variety of cell types against oxidative injury 
and are widely used in therapeutic contexts. These agents 
exert protective effects in experimental models of dilated 
cardiomyopathy, arteriovenous failure [20], myocardial 
infarction [21], and global stroke [3]. GLP-1Rs are highly 
expressed throughout the brain [22, 23], and GLP-1 and 
GLP-1R agonists such as Ex-4 completely protect against 
glutamate–induced neuronal death [24] and stroke injury 
[3]. Ex-4 has been shown to attenuate neointimal hyper-
plasia after vascular injury [25] and prevent lipotoxicity-
induced apoptosis in murine pancreatic β-cells through 
activation of Akt and inhibition of the mitochondrial 
pathway [26]. Ex-4 also reduces damage to vascular 
endothelial cells by high levels of glucose and tumor 
necrosis factor-α by inhibiting p38 mitogen-activated 
protein kinase expression and the nuclear transloca-
tion of nuclear factor kappa B (NF-κB) [27]. Lir protects 
against oxidative stress and diabetic nephropathy via a 
PKA-mediated inhibition of renal nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase [28].
Given the prevalence of stroke in diabetic patients, thera-
peutic strategies for reducing stroke-induced motor and 
cognition deficits and bladder dysfunction in these patients 
after acute stroke are of interest. Based on the previously 
established protective effects of GLP-1 analogs against oxi-
dative stress and cell death, we investigated the effects of 
Ex-4 and Lir on cerebral microcirculation, oxidative stress-
related protein expression, cognitive and motor behaviors, 
and parasympathetic nerve-mediated micturition function 
after MCAO in the db/db mouse model of diabetes.
Results
Ex‑4 and Lir partially alleviate MCAO‑induced reductions 
in cerebral microcirculation
Figure  1 shows changes in cerebral microcirculation in 
the right hemisphere of db/db mice following MCAO 
injury. Cerebral microcirculation was significantly 
reduced throughout the 12 h following MCAO compared 
to that in the control group (Fig.  1a, b). Within 6–12  h 
after MCAO, mice treated with Ex-4 or Lir showed sig-
nificantly increased microcirculation compared to the 
MCAO group. There was no significant difference in the 
percentage change in perfusion units (PU) between mice 
treated with Ex-4 and Lir. Brain edema was not observed 
via T-2-weighted MRI in control group. Marked fore-
brain edema in the section area 12 h after MCAO group 
was significantly increased in the MCAO group com-
pared to that in the control group (Fig.  1c, d). Between 
mice treated with Ex-4 or Lir significantly decreased 
edema area compared to MCAO group (Fig. 1c, e).
Ex‑4 reduces MCAO‑induced expression of oxidative stress 
and apoptosis markers
As shown in Fig.  2, MCAO markedly increased stain-
ing for the ROS marker dihydroethidium (DHE) and the 
inflammatory marker intercellular adhesion molecule-1 
(ICAM-1) in the right brainstem of db/db mice. Mice 
subjected to MCAO also showed increased caspase 3 
expression and terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL), which 
are markers of apoptosis. Staining for DHE, ICAM-1, 
caspase 3 and TUNEL was greater at 12  h than at 3 or 
6  h after MCAO. These MCAO-induced increases in 
oxidative stress and apoptotic markers were markedly 
decreased by Ex-4 treatment (Fig. 2u–y).
MCAO also significantly increased the levels of brain 
DHE labeling (Fig.  3a), blood and brain reactive oxygen 
species (ROS) (Fig.  3b, c), and brain malondialdehyde 
(MDA) (Fig.  3d), a by-product of lipid peroxidation that 
indicates oxidative stress. Levels of these markers were 
higher at 12 h than at 3 or 6 h after injury in the MCAO 
group but were significantly reduced by Ex-4 and Lir treat-
ments (P < 0.05). Ex-4 and Lir displayed similar effects in 
reducing brain and blood markers of oxidative stress.
(see figure on next page.) 
Fig. 1 Effects of exendin‑4 and liraglutide on cerebral microcirculation after injury in db/db mice. a Schematic diagram showing the area of micro‑
circulation measurement. b Representative full field laser perfusion images showing cerebral microcirculation in mice treated with exendin‑4 (Ex‑4) 
or liraglutide (Lir) following middle cerebral artery occlusion (MCAO) injury. Percentage change in perfusion units (PU), presented as mean ± stand‑
ard error of the mean (SEM; n = 6 per condition). Groups were compared using two‑way analysis of variance (ANOVA) with a post hoc Bonferroni 
adjustment for pairwise comparisons. *P < 0.05 compared to the MCAO group. c The T2‑weight magnetic resonance imaging series revealed that 
after MCAO 12 h group marked brain edema (hight signal intensity area) had a significantly higher percentage in the red line section area d in com‑
parison with control group. e After Exendin‑4 and Liraglutide treatment decrease the brain edema percentage more significantly than the group of 
MCAO. *P < 0.05 compared to the control group, aP < 0.05 compared to the MCAO group
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Ex‑4 and Lir inhibit MCAO‑induced inflammatory protein 
expression
Expression of the inflammation-related proteins ICAM-
1, NF-κB p50, and NF-κB p65 in db/db mice following 
MCAO, as measured by western blotting [29], is shown 
in Fig.  4. ICAM-1 expression was significantly higher 
greater at 12 h than at 3 h after MCAO and than in con-
trols; this increase was significantly suppressed by Ex-4 
and Lir treatments. Ex-4 decreased ICAM-1 expres-
sion to a slightly greater extent than did Lir, although 
this difference was not significant. NF-κB p50 and p65 
expression in the right hemisphere of cortical homogen-
ate was significantly increased 6 and 12 h after MCAO 
compared to controls (Fig.  4b, d). Ex-4 and Lir exerted 
similar effects on MCAO-induced increases in cortical 
NF-κB p50 and p65 expression. These increases were 
significantly inhibited 12  h after MCAO by Ex-4 and 
Lir treatments. As shown in Fig.  4e, the green NF-κB 
fluorescence was greatly increased in the section of cer-
ebral cortical area 12 h after MCAO in comparison with 
the matched-time control mice. The enhanced NF-κB 
fluorescence was effectively depressed in the Lir- or 
Ex-4-treatment group 12  h after MCAO. According to 
cortical cellular morphology, NF-κB fluorescence seems 
to be expressed in both neuronal and glial cells 12 h after 
MCAO.
Fig. 2 Effects of exendin‑4 on MCAO‑induced markers of oxidative stress, inflammation, and apoptosis. Shown are dihydroethidium (DHE) labeling 
of reactive oxygen species (ROS; a, f, k, p, u), intercellular adhesion molecule‑1 (ICAM‑1; b, g, l, q, v), DHE and ICAM‑1 merged (c, h, m, r, w) caspase 
3 (d, i, n, s, x, indicated by brown color) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL; e, j, o, t, y, indicated by brown 
color) at 3, 6, and 12 h after MCAO injury in db/db mice. MCAO markedly increased DHE, ICAM‑1, Caspase 3 and TUNEL labeling; these effects were 
offset by Ex‑4 treatment (magnification DHE, ICAM‑1 400; and magnification Caspase3, TUNEL 200)
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Ex‑4 and Lir repress MCAO‑induced expression 
of apoptotic markers
Figure 5a shows representative western blots of the apop-
tosis-related proteins Bax, B-cell lymphoma-2 (Bcl-2), 
caspase 3, and poly-(ADP-ribose)-polymerase (PARP) in 
the cortex of db/db mice after MCAO. The ratio of Bax 
to Bcl-2 expression (Fig. 5b), as well as the levels of cas-
pase 3 (Fig.  5c) and PARP (Fig.  5d), were significantly 
higher than in control mice at 3, 6, and 12 h after MCAO 
(P < 0.05). These increases were significantly attenuated 
by Ex-4 and Lir treatments 12 h after MCAO (P < 0.05). 
The expression of caspase 3 and PARP showed non-sig-
nificant decreases in mice treated with Ex-4 compared to 
those treated with Lir.
Ex‑4 and Lir treatments attenuate MCAO‑induced 
decreases in manganese superoxide dismutase expression
The expression of the mitochondrial antioxidant enzyme 
manganese superoxide dismutase (MnSOD) was sig-
nificantly reduced at 6 or 12 h after MCAO injury when 
compared to control mice (Fig. 5e); this effect was signif-
icantly attenuated at 12  h after MCAO by Lir and Ex-4 
treatment (P < 0.05). Although Ex-4 resulted in a larger 
increase in MnSOD expression than did Lir, this differ-
ence was not significant.
Ex‑4 and Lir enhance levels of phosphorylated Akt 
and endothelial nitric oxide synthase in the brain
Figure  5f shows representative western blots of phos-
phorylated Akt (p-Akt) and endothelial nitric oxide syn-
thase (p-eNOS) in the cortex of db/db mice after MCAO. 
Although neither p-Akt (Fig.  5g) nor p-eNOS (Fig.  5h) 
expression was affected by MCAO, the expression of 
both proteins was significantly increased in mice treated 
with Ex-4 or Lir 12 h after MCAO (P < 0.05). The expres-
sion of p-Akt and p-eNOS was similar in Ex-4- and Lir-
treated animals.
Ex‑4 treatment ameliorates MCAO‑induced motor 
and cognitive deficits
The effects of MCAO on motor and cognitive func-
tion were evaluated using a sniffing behavior paradigm. 
MCAO caused motor deficits, as shown by significant 
decreases in the average center velocity (Fig. 6b, b1) and 
elongation ratio (Fig. 6b2) at 12 h, 3 days, or 7 days after 
MCAO injury when compared to the time-match of 
control group (Fig.  6a–a2). Ex-4 treatment significantly 
ameliorated these MCAO-induced motor deficits at 
each time point. Further, the MCAO-induced increase in 
center velocity (Fig. 6c, c1) and elongation ratio were sig-
nificantly improved by Ex-4 at 7 days after MCAO com-
pared to 12 h after MCAO (Fig. 6c, c2) (P < 0.05).
Cognitive function was also significantly impaired by 
MCAO (Fig. 6b3, b4), as indicated by an increased per-
centage of non-target sniff time (Fig. 6c3) and decreased 
percentage of target sniff time (Fig. 6c4) at 12 h, 3 days, 
and 7 days after MCAO injury. Ex-4 treatment partially 
attenuated this cognition deficit, as the times spent 
investigating the non-target and target objects were 
Fig. 3 Effects of exendin‑4 and liraglutide on MCAO‑induced ROS 
production. Shown are DHE (a), blood ROS (b), brain ROS (c) and 
brain malondialdehyde (MDA) content (d) at 3, 6, and 12 h after 
MCAO injury in db/db mice. MCAO significantly increased DHE 
expression, blood and brain ROS levels, and brain MDA content, 
whereas exendin (Ex) and Lir partially occluded these effects. Data are 
presented as mean ± SEM (n = 6 per condition). Groups were com‑
pared using two‑way ANOVA with a post hoc Bonferroni adjustment 
for pairwise comparisons. *P < 0.05 compared to controls; aP < 0.05 
compared to 3 h after MCAO; bP < 0.05 compared to 6 h after MCAO; 
#P < 0.05 compared to 12 h after MCAO
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Fig. 4 Effects of exendin‑4 and liraglutide on MCAO‑induced inflammatory protein expression. a Typical western blots of nuclear factor‑κB (NF‑κB) 
p65, and ICAM‑1 in cortical extracts at 3, 6, or 12 h after MCAO. Densitometry of b NF‑κB50, c ICAM‑1, and d NF‑κB p65 bands normalized to β‑actin. 
Data are presented as mean ± SEM (n = 6 per condition). e The expression of NF‑κB (green fluorescence) was markedly enhanced in the cerebral 
cortical area 12 h after MCAO in comparison with the matched‑time control mice. The increased NF‑κB fluorescence was efficiently attenuated in 
the Lir‑ or Ex‑4‑treatment group 12 h after MCAO. The NF‑κB fluorescence seems to be expressed in both neuronal and glial cells 12 h after MCAO 
(Magnification 400×). Groups were compared using two‑way ANOVA with a post hoc Bonferroni adjustment for pairwise comparisons. *P < 0.05 
compared to controls; aP < 0.05 compared to 3 h after MCAO; bP < 0.05 compared to 6 h after MCAO; #P < 0.05 compared to 12 h after MCAO
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Fig. 5 Effects of exendin‑4 and liraglutide on MCAO‑induced apoptosis‑related protein expression. Typical western blots of Bax, B‑cell lymphoma 
2 (Bcl‑2), caspase 3, poly‑(ADP‑ribose)‑polymerase (PARP), and manganese superoxide dismutase (MnSOD) expression a and f phosphorylated Akt 
(p‑Akt) and endothelial nitric oxide synthase (p‑eNOS) levels b in the right cerebral cortex of sham‑operated control or MCAO‑injured db/db mice 
at 3, 6, or 12 h after surgery. Densitometric quantification of the ratio of Bax/Bcl‑2 bands (b) and caspase 3 (c), PARP (d), MnSOD (e), p‑Akt (g), and 
p‑eNOS (h) bands normalized to β‑actin. Data are presented as mean ± SEM (n = 6 per condition). Groups were compared using two‑way ANOVA 
with a post hoc Bonferroni adjustment for pairwise comparisons. *P < 0.05 compared to control; aP < 0.05 compared to 3 h after MCAO; bP < 0.05 
compared to 6 h after MCAO; #P < 0.05 compared to 12 h after MCAO
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Fig. 6 Effects of exendin‑4 on MCAO‑induced motor and cognitive deficits in db/db mice at 12 h (h), 3 and 7 days (d) after MCAO. a, a1–a4 
Experimental design and representative activity traces of control, b, b1–b4 MCAO‑injured, and c, c1–c4 MCAO‑injured mice treated with Ex‑4 at 
12 h, 3 days, and 7 days after injury. Motor parameters were (a1, b1, c1) velocity calculated using the body center trace and (a2, b2, c2) elongation 
ratio; cognitive parameters were (a3, b3, c3) non‑target and (a4, b4, c4) target sniffing bousts. Groups were compared using two‑way ANOVA with 
a post hoc Bonferroni adjustment for pairwise comparisons. *P < 0.05 compared to the time‑matched control group; aP < 0.05 compared to the 
time‑matched MCAO group; bP < 0.05 compared to MCAO + Ex‑4 group at 12 h after injury
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significantly decreased and increased, respectively, at 3 
and 7 days after MCAO in Ex-4-treated mice. We further 
found that the time spent exploring the target object was 
significantly increased at 7  days after MCAO compared 
to 12 h after MCAO in Ex-4-treated mice.
Ex‑4 and Lir treatments attenuate MCAO‑ induced voiding 
impairments
Figure  7 shows the protective effects of Ex-4 and Lir 
against MCAO-induced bladder dysfunction in db/db 
mice. Figure 7a shows a representative recording of intra-
vesical pressure (IVP) before and after MCAO injury in 
control, MCAO, Ex-4-treated MCAO, and Lir-treated 
MCAO groups. MCAO significantly reduced voiding 
contractions (Fig. 7b) and increased nonvoiding contrac-
tions (Fig. 7c); these effects were significantly attenuated 
by treatment with Ex-4 and Lir.
Discussion
The results of this study demonstrate protective effects of 
the GLP-1 analogs Ex-4 and Lir against MCAO-induced 
cerebral blood flow impairment, blood and brain ROS 
production, oxidative stress-related and inflammatory 
protein expression, and impairments in motor and cogni-
tive function and bladder contraction in the db/db mouse 
model of diabetes. MCAO decreased cerebral microcir-
culation in db/db mice and increased blood and brain 
ROS production and NF-κB, ICAM-1, caspase 3, and 
Fig. 7 Effects of exendin‑4 and liraglutide on MCAO‑induced bladder dysfunction in db/db mice. a Typical intravesical pressure (IVP) traces before 
and after surgery in control, MCAO, Ex‑4‑treated MCAO, and Lir‑treated MCAO groups. Voiding contractions (a) and nonvoiding contractions (n) 
are labeled. b MCAO significantly reduced voiding contractions and c increased nonvoiding contractions; these effects were partially reversed by 
Ex‑4 and Lir treatments. Groups were compared using two‑way ANOVA with a post hoc Bonferroni adjustment for pairwise comparisons. *P < 0.05 
compared to the control group; #P < 0.05 compared to the MCAO group
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TUNEL expression. Ex-4 and Lir treatment in mice sub-
jected to MCAO resulted in significantly higher cerebral 
blood flow, preservation of MnSOD expression, lower 
blood and brain ROS counts, and lower NF-κB, ICAM-1, 
caspase 3 and TUNEL expression compared to untreated 
MCAO mice. Expression of p-Akt and p-eNOS expres-
sion was not affected by MCAO but was significantly 
enhanced by Ex-4 and Lir treatments. Ex-4 and Lir treat-
ments also mitigated MCAO-induced motor and cogni-
tive deficits and micturition dysfunction, as indicated by 
reduced voiding contractions and increased nonvoiding 
contractions. As shown in the Fig. 1, magnetic resonance 
imaging data show that MCAO-induced brain edema 
was significantly reduced by Lir and Ex-4 treatments.
Several previous studies indicate that GLP-1 and GLP-
1R agonists are neuroprotective [30, 31]. These mole-
cules are small enough to cross the blood–brain barrier 
[32–34], and GLP-1Rs are widely expressed throughout 
the brain. Our recent data indicate that Ex-4 treatment 
reduces stroke-induced frontal cortex edema, endo-
plasmic reticulum stress, apoptosis, and upregulation 
of aquaporin 4, glial fibrillary acid protein, and ICAM-1 
[3]. Briyal et al. [35] demonstrated that Ex-4 significantly 
protected rats from MCAO-induced cerebral ischemia, 
reducing the infarct volume by up to 27  % and reduc-
ing neurological deficits and oxidative stress parameters. 
These results suggest that Ex-4 and Lir are attractive can-
didates for reducing oxidative injury and inflammation 
in the brain. Elucidation of the molecular mechanisms 
of Ex-4 and Lir action in the brains of diabetic animals 
will require further investigation, although some reports 
have demonstrated that Ex-4 treatment in diabetic rats 
before and after stroke reduces ischemic brain damage 
by arresting microglial infiltration and increasing stroke-
induced neural stem cell proliferation [36].
Brain ischemia and reperfusion initiate a complex 
cascade of metabolic events, several of which generate 
nitrogen and oxygen free radicals that mediate much of 
the damage that occurs after transient brain ischemia 
[37]. MCAO has previously been shown to increase the 
activity of NADPH oxidase and nitric oxide synthases in 
neurons, vascular endothelium, infiltrating neutrophils 
and macrophages, activated microglia, and astrocytes 
[3]; in the present study, we show that MCAO increases 
ICAM-1 expression and DHE labeling of ROS. We found 
that blood and brain ROS levels were significantly ele-
vated after MCAO, especially at 12 h after injury. NF-κB 
nuclear translocation and ICAM-1 upregulation in the 
damaged brain cause leukocyte infiltration, adhesion, 
and migration, which lead to ROS production, inflam-
mation, and oxidative injury. In this study, we observed 
that Ex-4 and Lir treatment significantly inhibited 
MCAO-induced NF-κB and ICAM-1 activation and ROS 
production. Teramoto et al. [34] demonstrated that sup-
pression of oxidative damage is a key factor in neuropro-
tection. Although the exact mechanisms of Ex-4- and 
Lir-mediated reductions in MCAO-induced ROS pro-
duction remain unclear, we suggest that Ex-4 and Lir act 
as antioxidants and anti-inflammatory agents to decrease 
MCAO-induced brain inflammation and injury.
Insulin and glucose levels can also influence brain 
injury. Evidence from several studies indicates that 
increased insulin can mitigate damage induced by 
ischemia and reperfusion. Hui et  al. [38] showed that 
pretreating rats with insulin before cerebral ischemia sig-
nificantly increases the number of surviving CA1 pyrami-
dal cells in the hippocampus after 5 days of reperfusion. 
Another study reported that, in diabetic rats subjected 
to cerebral ischemia and reperfusion, insulin treat-
ment decreased brain lesion volume, as well as basal and 
injury-induced apoptotis [39]. Our results show that Ex-4 
exerts protective effects against ischemia-induced dam-
age in db/db mice, which have higher serum insulin levels 
than normal mice. One previous study reported that Ex-4 
treatment did not influence serum insulin levels in db/db 
mice [40]. Together, these results suggest that Ex-4 may 
be an appropriate therapeutic agent in diabetic stroke 
patients.
The effects of GLP-1 agonist treatment on the signal-
ing pathways that affect oxidative stress- and apopto-
sis-related protein expression have been documented 
previously. Ex-4 directly improves impaired endothe-
lium-dependent vasodilation of aortas via cAMP/
AMPK-eNOS pathway [41]. Ex-4 also attenuates neoin-
timal hyperplasia after vascular injury via camp/PKA 
pathway and inhibits TNFα production by peritoneal 
macrophages in response to inflammatory [25]. GLP-1 
analog, Lir, promote neuronal survival and attenuate 
MDA oxidative stress and anti-apoptosis following by 
cerebral ischemia [35]. Ex-4 upregulates cAMP and trig-
gers CREB phosphorylation [34], leading to the upregula-
tion of Bcl-2 [42], which in turn inhibits apoptosis [43]. 
Our results show that Ex-4 and Lir significantly decrease 
Bax expression and the Bax/Bcl-2 ratio, leading to 
reduced apoptosis, possibly through stimulation of Akt 
and eNOS signaling. Akt pathway activation in ischemic 
regions has been reported to reduce ischemia- and rep-
erfusion-induced damage by modulating the endothelial 
nitric oxide pathway [44]. In this study, we observed that 
Ex-4 and Lir treatments significantly increased p-Akt and 
p-eNOS levels following MCAO, indicating the recruit-
ment of protective signaling pathways against oxidative 
stress.
Fu et al. [45] showed that cytokine and neuronal NOS 
levels are elevated in the lumbosacral spinal cord of rats 
subjected to MCAO, far from the injury site. In the spinal 
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cord, tumor necrosis factor-α and interleukin-1β immu-
noreactivities were mainly localized to the ventral horn 
motor neurons contralateral to the site of MCAO. Neu-
ronal NOS immunoreactivity and NADPH-diaphorase 
staining in the spinal cord were also markedly increased 
in response to MCAO. This, together with some neuronal 
deaths, may be linked to the dysfunction of the latter in 
a clinical stroke [45]. A previous study has demonstrated 
significant reductions in voided volume per micturition 
and significantly increased voiding frequency follow-
ing mild forebrain ischemia in rats [14]. Consistent with 
these results, our unpublished data show that MCAO 
evokes frontal cortex injury in rats and inhibits effer-
ent pelvic nerve activity, resulting in impaired voiding 
function, especially phase 2 of the voiding contraction, 
which is regulated by pelvic nerve activity. Ex-4 treat-
ment restores pelvic parasympathetic nerve activity in 
these studies, indicating its protective effect against brain 
injury. As our data indicate that Ex-4 and Lir treatments 
ameliorate MCAO-induced bladder hyperactivity, we 
believe that Ex-4 or Lir may be promising therapeutic 
strategies for the treatment of stroke-induced bladder 
hyperactivity.
Conclusion
Diabetic mice treated with GLP-1 agonists after ischemia/
reperfusion injury (MCAO) exhibited increased cerebral 
blood flow, decreased ROS production, and decreased 
expression of oxidative stress-, inflammation-, and 
apoptosis-related proteins in the brain. Treatment with 
GLP-1 agonists also mitigated MCAO-evoked cognitive 
and motor impairments and stimulated protective signal-
ing pathways and antioxidant MnSOD expression in the 
brain area that mediates parasympathetic/pelvic nerve-
mediated voiding contractions. These results suggest that 
GLP-1 agonists may be useful in the treatment of cerebral 
and cardiovascular complications of diabetes.
Methods
Animals
The db/db mouse model of diabetes, which undergoes 
spontaneous, apoptotic destruction of pancreatic β-cells, 
was used in this study. Male db/db mice at 6–8  weeks 
of age were housed in a temperature-controlled facility 
at the Experimental Animal Center at I-Shou University 
(Kaohsiung, Taiwan) with a 12  h light/dark cycle. Ani-
mal care and experimental protocols were in accord-
ance with guidelines prescribed by the National Science 
Council of the Republic of China (NSC1997). The animal 
studies were reviewed and approved by the Institutional 
Animal Care and Use Committee of I-Shou University 
(IACUC Protocol No. AUP-95-55-001 and Approval No. 
IACUC-ISU-95004).
Middle cerebral artery occlusion
Transient MCAO using an intraluminal suture was 
performed as previously described [46]. Mice were 
anesthetized with chloral hydrate (400 mg/kg) in 25 % O2-
enriched room air with spontaneous ventilation. Animals 
were placed in the supine position, and a midline incision 
was made along the neck. Using a surgical microscope, 
a silicone-coated 7.0 nylon filament (0.24  mm in diam-
eter) was inserted through a small incision in the exter-
nal carotid artery and advanced approximately 7  mm 
through the internal carotid artery towards the Circle of 
Willis and to the point of origin of the middle cerebral 
artery. After 60 min, the filament was removed to restore 
blood flow to the brain, and reperfusion was allowed for 
0, 3, 6, or 12 h (n = 6 animals per group). Body tempera-
ture was maintained within the physiological range dur-
ing MCAO and reperfusion.
Cerebral cortex microcirculation measurements
Ex-4 and Lir (0.1  mg/mL) were administered intraperi-
toneally during the 0, 3, 6, or 12  h reperfusion periods 
following MCAO. Mice in the control group (0 h of treat-
ment; n =  6) were treated with normal saline. We con-
tinuously measured cerebral cortex microcirculation in 
the control and DM mice during administration of vehi-
cle, Ex-4, or Lir 3 or 6 h before or 12 h after MCAO as 
described previously [3]. A full field laser perfusion imag-
ing system (moorFLPI; Moor Instruments, Wilmington, 
DE, USA) was used to continuously monitor microcir-
culation. Microcirculation in each region of interest was 
recorded in perfusion units, an arbitrary unit related to 
the product of average speed and the concentration of 
moving red blood cells in the tissue sample volume. The 
images were analyzed in real time using moorFLPI soft-
ware version 3.0 (Moor Instruments Ltd.).
Cerebral edema measurement by T2‑weighted magnetic 
resonance imaging (MRI)
MRI was carried out in the animals using a Bruker Bio-
spec 7-T MRI system as described previously [3]. Ex-4 
and Lir (0.1  mg/mL) were administered intraperito-
neally 12  h reperfusion periods following MCAO. Mice 
in the control group (0  h of treatment; n  =  6) were 
treated with normal saline. Anesthesia was induced with 
5  % halothane and maintained with 1.5  % halothane 
(both concentrations prepared in O2:N2O, 70:30 by vol-
ume). Control or DM rats treated with vehicle, Ex-4 or 
Lir post 12-h CAO were intubated and mechanically 
ventilated at a rate of 60 breaths/min. Heart rates and 
respiratory rates were monitored throughout the proce-
dure, and body temperature was maintained at 37 °C. A 
rapid-acquisition relaxation enhancement T2-weighted 
sequence was used to determine the precise lesion 
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location, with a rapid-acquisition relaxation enhance-
ment factor (RARE) of 16, a repetition time of 5086 ms, 
and an echo time of 70.1  ms. The in-plane resolution 
was 250  ×  250  ×  250  µm and 15 slices were acquired. 
A second T2-weighted image set of 25 contiguous slices 
was acquired at the lesion site (RARE factor =  16, rep-
etition time =  5086  ms, echo time =  70.1  ms) with an 
in-plane resolution of 117  ×  117  ×  500  µm. Infarct 
areas, outline in white, were calculated from each MRI 
image using image analysis software (Adobe Photoshop 
CS4). The percentage of edema was calculated as: Brain 
edema (%)  =  Infarct area/(Infarct area and unaffected 
area) × 100 %.
Motor and cognitive function assessment
Motor and cognitive function were evaluated in Ex-4- 
or Lir-treated db/db mice using a novel sniffing behav-
ior test before MCAO and 12 h, 3 days, or 7 days after 
MCAO. In the conditioning session, the animals 
were placed individually in a conditioning chamber 
(60 ×  60 ×  60  cm) for 2  h. Each chamber contained 2 
objects: sawdust (nontarget object) and feed (target 
object). For the test session, the animal was placed in 
the same chamber for 15 min, and activity was recorded 
using a high-throughput-screening top-view camera 
(STD-CA67D-IR; Sony, Tokyo, Japan) and ObjectS-
can behavior analysis software (Clever Sys Inc., Reston, 
VA, USA) [3, 47]. Time spent exploring each object was 
recorded to assess cognitive behavior. All nose entries 
within 2 cm of the object were recorded as time explor-
ing the object. Animals that spent <7 min exploring the 
objects during the test session were excluded from the 
analysis. Nose and center traces were recorded, and 
velocity and elongation ratio were analyzed to evaluate 
motor function. The objects and arenas were thoroughly 
cleaned with 70 % isopropanol between trials.
Cystometry
Mice were anesthetized via subcutaneous injection of 
urethane (1.2  g/kg). An incision was then made in the 
caudal aspect of the abdomen to expose the bladder, a 
suture was placed in the dome of the bladder using 6-0 
silk, and a PE-50 bladder catheter was inserted through 
the apex of the bladder dome and connected via a T-tube 
to an infusion pump and P23 ID pressure transducer 
(Gould Instruments, Cleveland, OH, USA), as described 
previously [48]. IVP was recorded continuously using 
a PowerLab 16S system (ADInstruments, Sydney, Aus-
tralia). Sterile saline (0.9  %) was infused into the blad-
der at a rate of 0.8 mL/h. Mice were placed in a ventral 
recumbent position on a heating pad, and IVP was con-
tinuously recorded for at least 90  min for each mouse. 
Data were analyzed from traces of at least 5 consecutive 
voiding episodes obtained after a consistent voiding pat-
tern had been achieved. Parameters measured included 
the intercontractile interval (defined as the time between 
peaks in IVP) and the maximal IVP associated with each 
voiding episode. Contractions with a contractile ampli-
tude lower than the maximal IVP without actual voiding 
were designated as nonvoiding contractions. Mice were 
euthanized by an intraperitoneal injection of pento-
barbital sodium (75  mg/kg) at the conclusion of data 
collection.
Measurement of ROS production, NF‑κB, ICAM‑1 
and apoptosis
Mice were sacrificed at the end of the experiment, and 
we conducted DHE 2,7-diamino-10-ethyl-9-phenyl-
9,10-dihydrophenanthridine) and ICAM-1 staining to 
assess ROS production in the brain after MCAO. Brain 
tissue samples were frozen in Tissue-Tek optimal cut-
ting temperature compound (Sakura Finetek, Torrance, 
CA, USA) and cut into 10-mm cross sections. To assess 
oxidative stress and apoptosis, fluorescent DHE and 
ICAM-1 stains and colorimetric caspase 3 and TUNEL 
stains were applied to each cross section for 5  min at 
room temperature. Images from brain stem sections were 
captured using a Leica DMRD fluorescence microscope 
(Leica Microsystems, Wetzlar, Germany) [49]. The brain 
tissue for assessment of NF-κB expression were washed 
with phosphate-buffered saline, stained with NF-κB 
polyclonal antibody (R&D Systems, Minneapolis, MN, 
USA) and mounted in mounting medium (Lecia). The 
slides were scanned under a Lecia TCS SP3 laser confocal 
microscope to obtain the confocal images.
As an additional measure of ROS levels in brain tis-
sue, 1  mg samples were obtained after MCAO and 
homogenized in 0.2 mL of saline. Tissue ROS levels were 
immediately measured using the lucigenin-enhanced 
chemiluminescence method, which has been used pre-
viously to measure increases in ROS production in 
response to neurogenic inflammation [49]. A 100-s back-
ground luminescence measurement was recorded using a 
chemiluminescence analyzing system. Lucigenin solution 
(0.1  mM in phosphate-buffered saline, pH 7.4; 0.5  mL) 
was then added to the sample, and chemiluminescence 
was measured for 10 min. The area under the chemilumi-
nescence curve was integrated to obtain the total chemi-
luminescence signal, and the background luminescence 
was subtracted. Duplicate tests were performed for each 
sample. Results are expressed as chemiluminescence 
counts per 10 s. A similar technique was used to meas-
ure blood ROS production, as described previously [48]. 
Lipid peroxidation was measured in cortical samples 
using an MDA colorimetric/fluorometric assay kit (Biovi-
sion, Milpitas, CA, USA).
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Western blotting
Western blotting was used to measure cortical levels 
of the apoptosis-related proteins Bax, Bcl-2, caspase 3, 
PARP, e-NOS, NF-κB, ICAM-1 and MnSOD. In brief, 
whole cortical lysate proteins (20 μg/well) were electro-
phoretically separated on 10 % polyacrylamide gels and 
transferred to nitrocellulose membranes (GE Health-
care, Westborough, MA, USA). The membranes were 
blocked and then incubated overnight at 4  °C with 
antibodies raised against the following proteins: Bax 
(AB2916; EMD Millipore, Billerica, MA, USA), Bcl-2 
(Transduction, Bluegrass-Lexington, KY, USA), the 
17 kDa activated cleavage product of caspase 3 (CPP32/
Yama/Apopain; human full-length caspase 3 fusion 
protein containing a histidine-6 tag), the p85  N-ter-
minal cleavage product of PARP (Promega, Madi-
son, WI, USA); eNOS (BD Biosciences, San Jose, CA, 
USA), NF-κB (R&D Systems, Minneapolis, MN, USA), 
ICAM-1 (R&D Systems), and MnSOD (Enzo Life Sci-
ences, Farmingdale, NY, USA). Antibodies were diluted 
200- to 2000-fold. Membranes were then incubated for 
1 h at room temperature with anti-rabbit or rabbit anti-
sheep IgG antibodies conjugated to horseradish peroxi-
dase (Vector Laboratories, Burlingame, CA, USA), and 
proteins were visualized using a commercial enhanced 
chemiluminescence kit (GE Healthcare). Band densities 
were determined semi-quantitatively by densitometry 
using an Alpha Innotech image analysis system (San 
Leandro, CA, USA) [50].
Statistical analysis
Data are presented as mean  ±  standard error of the 
mean. The 2-sample t test was used to compare data 
between 2 groups. Two-way analyses of variance with 
post hoc Bonferroni correction for pairwise comparisons 
were used to analyze differences between 3 groups. All 
statistical analyses were 2-tailed and considered signifi-
cant if P < 0.05. Statistical analyses were performed using 
SPSS v. 18.0 statistical analysis software (SPSS Inc., Chi-
cago, IL, USA).
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